

Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

**Listing of Claims**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)

4. (Presently Amended) A pharmaceutically acceptable composition for administration to a mammal, comprising:

a first ingredient being Eurycoma longifolia jack; and

a second ingredient effective to stimulate the production of cyclic GMP, wherein the second ingredient is a coumarin--;

wherein the composition is in a form adapted to be administered topically, the form being chosen from a moisturizer, a cream, a lotion, a gel, an ointment, and an emulsion.

5. (Original) The composition of claim 4, wherein said Eurycoma longifolia jack is present in said composition in a dosage amount in a range of about .02 mg/kg to about .06 mg/kg.

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Previously Amended) The composition of claim 4, wherein said coumarin stimulates the production of nitric oxide.

10. (Original) The composition of claim 9, wherein said coumarin is osthole.

11. (Original) The composition of claim 10, wherein said second ingredient is Cnidium monnier.

12. (Original) The composition of claim 11, wherein said Cnidium monnier is present in said composition in a dosage amount in a range of about .02 mg/kg to about .06 mg/kg.

13. (Previously Amended) The composition of claim 4, wherein said second ingredient inhibits the activity of at least one enzyme.

14. (Original) The composition of claim 13, wherein said enzyme is a phosphodiesterase.

15. (Original) The composition of claim 14, wherein said enzyme is phosphodiesterase-5.

16. (Original) The composition of claim 15, wherein said second ingredient is Cnidium monnier.

17. (Presently Amended) The composition of claim 4, further comprising a third ingredient for stimulating an increase in blood flow, the third ingredient being Epimedium sagittatum, and the third ingredient being provided in homeopathic form.

18. (Canceled)

19. (Presently Amended) The composition of claim ~~18~~ 17, wherein said Epimedium sagittatum is present ~~in said composition~~ in a dosage amount in a range of about .02 mg/kg to about .06 mg/kg.

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Previously Amended) The composition of claim 4, further comprising at least one vesicle operable for transporting said first ingredient and said second ingredient from a first site external to a body to a second site internal to said body.

25. (Cancelled)

26. (Cancelled)

27. (Previously Amended) The composition of claim 4, further including a plurality of active homeopathic ingredients.

28. (Original) The composition of claim 27, wherein the active homeopathic ingredients are chosen from abrotanum, adrenalinum, alfalfa, anacardium orientale, arsenicum album, avena sativa, baryta carbonica, baryta iodata, baryta muriatica, calcarea carbonica, calcarea fluorica, calcarea phosphorica, ferrum metallicum, fucus vesiculosus, hekla lava, helleborus niger, ignatia amara, lycopodium clavatum, nicotinamidum, secale cornutum, silicea, or thuja occidentalis.

29. (Cancelled)

Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

30. (Previously Amended) The composition of claim 4, further including a plurality of inactive ingredients, wherein said inactive ingredients are chosen from epimedium extract, aloe barbadensis extract, polyacrylamide, C13-14 isoparaffin, indole-3-carbinol, laureth 7, lecithin, saw palmetto extract, diazolidinyl urea, vitamin E acetate, sodium ascorbol phosphate, vitamin A, vitamin D3, or vitamin B2.

Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

31. (Cancelled)

32. (Cancelled)

33. (Presently Amended) A pharmaceutically acceptable composition for topical administration to a mammal, comprising:

a first ingredient effective to stimulate the synthesis of cyclic GMP, wherein said first ingredient includes a coumarin; and

at least one vesicle operable for transporting said first ingredient from a first site external to a body to a second site internal to said body--;

wherein the composition is in a form adapted to be administered topically, the form being chosen from a moisturizer, a cream, a lotion, a gel, an ointment, and an emulsion.

34. (Cancelled)

35. (Cancelled)

36. (Presently Amended) The composition of claim 33, wherein said first ingredient including a coumarin is Cnidium monnier.



Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

37. (Presently Amended) A pharmaceutically acceptable composition for administration to a mammal, comprising:

a first ingredient chosen from a hormone, a composition which potentiates a hormone, and mixtures thereof; ~~and~~

a second ingredient chosen from Morinda citrifolia and an extract of Morinda citrifolia; and

a third ingredient being a coumarin;

wherein the composition is in a form adapted to be administered topically, the form being chosen from a moisturizer, a cream, a lotion, a gel, an ointment, and an emulsion.

38. (Original) The composition of claim 37, wherein said first ingredient is growth hormone.

39. (Original) The composition of claim 37, further including a third ingredient including a luteinizing agent for stimulating the production of a hormone by a body.

40. (Original) The composition of claim 39, wherein said third ingredient is chosen from Mucuna Pruriens and Tribulus L. Terrestris.

41. (Original) The composition of claim 37, further including a plurality of active homeopathic ingredients.

42. (Original) The composition of claim 41, wherein the active homeopathic ingredients are chosen from abrotanum, adrenalinum, alfalfa, anacardium orientale, arsenicum album, avena sativa, baryta carbonica, baryta iodata, baryta muriatica, calcarea carbonica, calcarea fluorica, calcarea phosphorica, ferrum metallicum, fucus vesiculosus, hekla lava, helleborus niger, ignatia amara, lycopodium clavatum, nicotinamidum, secale cornutum, silicea, or thuja occidentalis.

43. (Original) The composition of claim 37, further including a plurality of inactive ingredients.

44. (Original) The composition of claim 43, wherein said inactive ingredients are chosen from epimedium extract, aloe barbadensis extract, polyacrylamide, C13-14 isoparaffin, laureth 7, lecithin, saw palmetto extract, diazolidinyl urea, vitamin E acetate, sodium ascorbol phosphate, vitamin A, vitamin D3, or vitamin B2.

45. (Original) The composition of claim 37, further including at least one vesicle operable for transdermally transporting said first ingredient and said second ingredient from a first site external to a body to a second site internal to said body.

46. (Original) The composition of claim 37 wherein said first ingredient includes an herbal extract including an element which synthesizes a catecholamine.

47. (Original) The composition of claim 46 wherein said element of said herbal extract is a hydroxylated amino acid.

48. (Original) The composition of claim 47 wherein said hydroxylated amino acid is L-dopa.

49. (Original) The composition of claim 46 wherein said catecholamine to be synthesized is dopamine.

50. (Original) The composition of claim 48 wherein said herbal extract is an extract of Mucuna Pruriens.

51. (Original) The composition of claim 46, wherein said first ingredient includes an herbal extract having an active component comprising a luteinizing agent.

52. (Original) The composition of claim 51, wherein said herbal extract is an extract of Tribulus L. Terrestris.

53. (Original) The composition of claim 46, wherein said element for synthesizing a catecholamine is L-dopa, said L-dopa operable to stimulate said mammal to synthesize dopamine.

54. (Original) The composition of claim 53, further comprising a third ingredient operable to prevent L-dopa from degrading in a mammal, thereby enhancing dopamine uptake in the mammal.

55. (Original) The composition of claim 54, wherein said third ingredient is Tribulus L. Terrestris or an herbal extract thereof.

56. (Original) The composition of claim 46, further including a plurality of active homeopathic ingredients.

57. (Original) The composition of claim 56, wherein the active homeopathic ingredients are chosen from abrotanum, adrenalinum, alfalfa, anacardium orientale, arsenicum album, avena sativa, baryta carbonica, baryta iodata, baryta muriatica, calcarea carbonica, calcarea fluorica, calcarea phosphorica, ferrum metallicum, fucus vesiculosus, hekla lava, helleborus niger, ignatia amara, lycopodium clavatum, nicotinamidum, secale cornutum, silicea, or thuja occidentalis.

58. (Original) The composition of claim 46, further including a plurality of inactive ingredients.

59. (Original) The composition of claim 58, wherein said inactive ingredients are chosen from epimedium extract, aloe barbadensis extract, polyacrylamide, C13-14 isoparaffin, laureth 7, lecithin, saw palmetto extract, diazolidinyl urea, vitamin E acetate, sodium ascorbol phosphate, vitamin A, vitamin D3, or vitamin B2.

60. (Original) The composition of claim 46, further including at least one vesicle operable for transdermally transporting said first ingredient and said second ingredient from a first site external to a body to a second site internal to said body.

Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

61. (Previously Added) The composition of claim 4, further comprising a third ingredient for stimulating an increase blood flow, the third ingredient being epimedium sagittatum.

Application Serial No. 10/790,417  
Applicant Charles A. Mesko  
Filed March 1, 2004  
Response to Office Action and Amendment  
Attorney Docket No. MESK-30

62. (Presently Amended) A pharmaceutically acceptable composition for administration to a mammal, comprising:

a first ingredient being *Eurycoma longifolia* jack; and

a second ingredient effective to stimulate the production of cyclic GMP, wherein the second ingredient inhibits the activity of at least one enzyme, the enzyme being a phosphodiesterase; and

a third ingredient being a coumarin;

wherein the composition is in a form adapted to be administered topically, the form being chosen from a moisturizer, a cream, a lotion, a gel, an ointment, and an emulsion.